CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.

Saved in:

Bibliographic Details
Title:	CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Authors:	Na K; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, College of Medicine, Yonsei University, Seoul, Republic of Korea., Kim DK; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, College of Medicine, Yonsei University, Seoul, Republic of Korea., Kim YS; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea., Hwang JY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kang SS; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Republic of Korea., Baek S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee CY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Yang SM; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Han YJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim MH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Han H; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim Y; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim JH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Jeon S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Byeon Y; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee JB; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Lim SM; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Hong MH; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Pyo KH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Cho BC; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Source:	Frontiers in immunology [Front Immunol] 2024 Mar 07; Vol. 15, pp. 1336246. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).
Publication Type:	Journal Article
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2024.1336246